HIPRA plans to produce 400 million doses of its SARS-CoV-2 HIPRA vaccine during 2022

Filtered by {{cFt}} Back to news
Home About HIPRA News HIPRA plans to produce 400 million doses of its SARS-CoV-2 HIPRA vaccine during 2022

HIPRA plans to produce 400 million doses of its SARS-CoV-2 HIPRA vaccine during 2022


The recombinant protein vaccine developed by HIPRA will start the clinical trial phase in June and will begin to be produced in October 2021

The president of the Government of Spain, Pedro Sanchez, visited the facilities of the multinational pharmaceutical company this Friday


The president of the Government of Spain, Pedro Sanchez, has visited the facilities of HIPRA's headquarters in Amer (Girona), a company that specializes in the research, production and marketing of vaccines, and with widespread experience in coronavirus.

He was accompanied by the Minister of Health, Carolina Dario, and the Minister of Science and Innovation, Pedro Duque. Alba Vergés, the health secretary of the Generalitat of Catalonia, also attended, among other authorities.

During the visit, the prime minister met with the Company's Management to follow at first hand the advances in research into the Covid-19 vaccine, whose clinical trials are expected to begin in June.

The vaccine, HIPRA SARS-CoV-2, is a recombinant protein vaccine that has been designed to optimize its safety and induce a potent immune response that neutralizes the Covid-19 virus. It will be kept between 2 and 8º C, which will facilitate its logistics and distribution.

The vaccination strategy covers the various vaccination scenarios, effectiveness against different variants and the most likely and increasingly necessary booster doses. Clinical trials are expected to conclude successfully, so that production can begin in October of this same year, with the aim of launching commercialization in late 2021, subject to obtaining the appropriate authorizations.

According to current HIPRA projections, 400 million doses are expected to be produced during 2022. By 2023, 1.2 billion doses could be reached.
 

HIPRA, with 50 years of experience in vaccine development, has a unique organizational model, which internally controls all processes in the value chain, generating unique know-how and making it a benchmark in vaccine research, production and marketing.

The HIPRA project is supported by the Spanish Agency of Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS), as well as the Ministries of Health, Industry and Science and Innovation.

HIPRA is currently also conducting a line of research in collaboration with Hospital Clinic in Barcelona for the development of a Covid-19 vaccine based on the mRNA of the virus.
 

KNOW MORE ABOUT THIS PROJECT
 

Share this on

The contents of this page are country specific and aimed specifically at prescribing veterinarians.

This product is not available in {{ preferredCountry.title }}.

You will be redirected to our global site. Click on continue to visit our global site (available in English).

Confirm that you are a veterinary professional:

This product is not available in {{ countrySelect.title }}.

You will be redirected to our global site. Click on continue to visit our global site (available in English).

  • I am a veterinarian (otherwise please contact a veterinary professional)

Select your country:

Country {{countrySelect.title}}
  • Global (available in English)
  • {{country.title}}